Failed Challenge with Quetiapine after Neuroleptic Malignant Syndrome with Conventional Antipsychotics

Hatch, Carie D.; Lund, Brian C.; Perry, Paul J.

doi:10.1592/phco.21.11.1003.34528

Cited by 24 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In December 2002, quetiapine represented 18.78% of the U.S. market for antipsychotic medications (IMS Data TRx Share, Dec. 2002 75 ). Five cases of NMS attributable to this drug have been reported in the literature, [69][70][71][72][73] with 4 males and 1 female. The mean age of these patients was 37.6 years (SD = 13.7).…”

Section: Nms Associated With Quetiapinementioning

confidence: 99%

Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs

Ananth¹,

Parameswaran²,

Gunatilake³

et al. 2004

J. Clin. Psychiatry

241

139

View full text Add to dashboard Cite

show abstract

Section: Nms Associated With Quetiapinementioning

confidence: 99%

Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs

Ananth¹,

Parameswaran²,

Gunatilake³

et al. 2004

J. Clin. Psychiatry

241

139

View full text Add to dashboard Cite

show abstract

“…Rechallenge with atypical agents has been done in the past [ 3 ]; however, there are scarce records of rechallenge with quetiapine. Of the few cases with quetiapine rechallenge after NMS, results are conflicting [ 4 , 5 ]. Here we discuss a case of NMS, its treatment, and subsequent successful rechallenge with the atypical agent quetiapine.…”

Section: Introductionmentioning

confidence: 99%

A Case of Neuroleptic Malignant Syndrome in a Profoundly Intellectually Disabled Patient with Successful Reintroduction of Antipsychotic Therapy with Quetiapine

Patel

Lilly

Ajayi

et al. 2018

Case Reports in Psychiatry

View full text Add to dashboard Cite

Neuroleptic Malignant Syndrome (NMS) is a rare condition clinically characterized by muscle rigidity, hyperthermia, autonomic instability, and acute mental status change. NMS is most often associated with use of high-potency first-generation antipsychotic medications; though, other neuroleptics have been implicated as well. NMS can be fatal with estimated mortality rates as high as 20%. Patients experiencing certain severe complications, including renal failure, have been associated with mortality as high as 50%, stressing the need for early recognition and treatment. Here we present the case of a 54-year-old male that initially presented with symptoms suspicious for sepsis, but who eventually developed a clinical picture consistent with NMS. We describe the diagnostic and treatment process leading to symptom remission. We then discuss our decision to reintroduce an atypical antipsychotic agent, quetiapine. This case illustrates the importance of early recognition of the signs and symptoms of NMS and the need to initiate treatment promptly in order to prevent complications, including death. This case also highlights the decision to resume antipsychotic pharmacotherapy after adequate resolution of NMS, demonstrating that it can be done so safely if started at low doses coupled with intensive monitoring of the patient.

show abstract

“…Some of the previous case reports reported recurrence of NMS after rechallenge with quetiapine, 13 while others have used it in patients with a history of NMS due to other agents 14 . In that case report, however, the authors cautioned that their findings of safe use of quetiapine should not be generalized.…”

mentioning

confidence: 99%